Showing 3971-3980 of 8742 results for "".
- Crown Laboratories Unveils New Corporate Brandinghttps://practicaldermatology.com/news/crown-laboratories-unveils-new-corporate-branding/2460037/Crown Laboratories is launching its new corporate branding. Their new tagline 'Skin Science for Life' highlights the company’s focus on aesthetic medicine, generic and branded dermatological prescription drugs, OTC and prestig
- National Emsculpt Week Kicks Offhttps://practicaldermatology.com/news/national-emsculpt-week-kicks-off/2460033/BTL has proclaimed the week of May 20 "National Emsculpt Week," in honor of the first and only non-invasive treatment to go beyond the elimination of fat cells to strengthen and define muscles. National Emsculpt Week was just registered with the National Day Calendar organization,
- Nestlé Enters into Negotiations to Sell Nestlé Skin Health to Consortium Led by EQT and ADIAhttps://practicaldermatology.com/news/nestle-enters-into-negotiations-to-sell-nestle-skin-health-to-consortium-led-by-eqt-and-adia/2460031/Nestlé has entered into exclusive negotiations with a consortium led by EQT and a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) for the sale of Nestlé Skin Health for a value of CHF 10.2 billion. Nestlé Skin Health
- Good Science Beauty Skincare Line Makes NYC Debuthttps://practicaldermatology.com/news/good-science-beauty-skincare-line-makes-nyc-debut/2460028/Spring always heralds the arrival many new skincare lines and products, and one of this season’s standouts may be Good Science Beauty, a line of six collagen-boosting products delivered via Silicon+ technology. The new skincare line was
- Sunscreen Chemicals Found in the Bloodstream: Experts React to the New Findingshttps://practicaldermatology.com/news/sunscreen-chemicals-found-in-bloodstream-experts-react-to-the-new-findings/2460023/Several active ingredients found in different sunscreens enter the bloodstream at levels that far exceed the FDA's recommended threshold without a government safety inspection, a new study in Journal of the American M
- Aesthetic Innovations Summit Coming to New Orleanshttps://practicaldermatology.com/news/aesthetic-innovations-summit-coming-to-new-orleans/2460022/Coming off an impressive inaugural meeting in 2018, the second annual Aesthetics Innovation Summit will unite over 300 of the most influential corporate, capital, and clinical leaders in New Orleans to collaborate on the development and adoption of new aesthetic treatments and technologies.
- BullDog Skincare for Men Unveils New Eco-Friendly Packaging, Razorhttps://practicaldermatology.com/news/bulldog-skincare-for-men-unveils-new-eco-friendly-packaging-razor/2460021/With sweet new packaging and a bamboo razor, Bulldog Skincare For Men is once again raising the bar in men’s skincare. The always vegan-friendly and anti-animal testing brand is now dramatically reducing its carbon footprint by using Braz
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma ski
- SkinBioTherapeutics Names New Executive Directorhttps://practicaldermatology.com/news/skinbiotherapeutics-names-new-executive-director/2460012/Stuart Ashman is the new executive director of SkinBioTherapeutics. Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial
- Xstrahl Introduces UpGraded Treatment System for Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/xstrahl-introduces-upgraded-treatment-system-for-non-melanoma-skin-cancer/2460011/Xstrahl Medical is launching its latest superficial radiotherapy treatment system to treat the full range of non-melanoma skin cancer cases. The new Xstrahl 150 system offers several features that enhance the capabilities of Xstrahl's curr